Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Adma Biologics 465 STATE ROUTE 17 RAMSEY NJ 07446 USA

www.admabiologics.com Employees: 685 P: 201-478-5552 F: 201-478-5553

Sector:

Medical

Description:

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 3,874,608
Enterprise Value, $K 3,843,798
Shares Outstanding, K 237,998
Float, K 229,668
% Float 96.50%
Short Interest, K 18,573
Short Float 7.80%
Days to Cover 7.22
Short Volume Ratio 0.40
% of Insider Shareholders 3.50%
% of Institutional Shareholders 75.68%

Financials:

Annual Sales, $ 426,450 K
Annual Net Income, $ 197,670 K
Last Quarter Sales, $ 134,220 K
Last Quarter Net Income, $ 36,430 K
EBIT, $ 167,140 K
EBITDA, $ 175,990 K

Growth:

1-Year Return 1.70%
3-Year Return 348.48%
5-Year Return 526.15%
5-Year Revenue Growth 1,352.98%
5-Year Earnings Growth 153.26%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.16 on 11/05/25
Next Earnings Date 03/02/26 [--]
Earnings Per Share ttm 0.59
EPS Growth vs. Prev Qtr 6.67%
EPS Growth vs. Prev Year 6.67%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ADMA Ratios

Ratio
Price/Earnings ttm 27.75
Price/Earnings forward 19.26
Price/Earnings to Growth N/A
Return-on-Equity % 36.52%
Return-on-Assets % 26.65%
Profit Margin % 46.35%
Debt/Equity 0.16
Price/Sales 8.20
Price/Cash Flow 30.25
Price/Book 9.05
Book Value/Share 1.81
Interest Coverage 10.02
60-Month Beta 0.49
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar